TLD is Sufficient for Post-Exposure Prophylaxis
Yes, tenofovir/lamivudine/dolutegravir (TLD) is sufficient and recommended for post-exposure prophylaxis (PEP). The 2025 CDC guidelines explicitly list dolutegravir plus (tenofovir alafenamide [TAF] OR tenofovir disoproxil fumarate [TDF]) plus (emtricitabine [FTC] OR lamivudine [3TC]) as a preferred regimen for nonoccupational PEP (nPEP) in adults and adolescents without relevant contraindications 1.
Guideline-Based Recommendations
The CDC 2025 recommendations establish TLD as one of two preferred nPEP regimens 1:
- Preferred option 1: Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)
- Preferred option 2: Dolutegravir plus (TAF or TDF) plus (FTC or 3TC) - which is your TLD regimen
Both carry the same evidence rating (recommendation, very low certainty of evidence), meaning they are equally endorsed 1.
Key Implementation Details
Duration: Complete the full 28-day course 1.
Timing: Initiate within 72 hours of exposure for maximum effectiveness. The sooner, the better - ideally within 24 hours 1.
Regimen selection factors 1:
- Renal function (TDF has more renal toxicity than TAF)
- Hepatic function
- Pregnancy status
- Drug interactions with concurrent medications
- Previous antiretroviral exposure (especially long-acting injectable PrEP)
- Source person's viral resistance history
- Pill burden and dosing frequency
- Cost and access considerations
Supporting Evidence
The IAS-USA 2024 guidelines similarly endorse DTG plus TXF/XTC combinations for treatment, reinforcing the regimen's efficacy 2. Research demonstrates excellent tolerability - a 2026 study showed DTG-based PEP achieved 96.67% completion rates with minimal adverse events 3.
Critical advantage: TLD offers superior gastrointestinal tolerability compared to older regimens, which directly improves adherence - the most important predictor of PEP success 3.
Common Pitfalls to Avoid
Do not use TLD if:
- Known or suspected dolutegravir resistance in the source person (switch to boosted darunavir-based regimen) 1
- Significant renal impairment with TDF formulation (use TAF instead or alternative regimen)
- First trimester pregnancy with DTG (though this is evolving - see below)
Pregnancy considerations: While DTG is now recommended for treatment in pregnancy 2, the CDC guidelines note limited data for DTG/3TC specifically during pregnancy and suggest individualized assessment for nPEP 1. However, DTG with TAF/FTC is the recommended treatment regimen in pregnancy 2, so TLD can be used with appropriate counseling.
Follow-Up Testing Protocol
After initiating TLD for PEP 1:
- Baseline: Rapid or lab-based Ag/Ab HIV test (add NAT if recent long-acting injectable PrEP exposure)
- Week 4-6: Lab-based Ag/Ab test plus diagnostic NAT
- Week 12: Final lab-based Ag/Ab test plus diagnostic NAT
If started within 24 hours and no missed doses: The 4-6 week testing may be deferred 1.
Transition to PrEP
For individuals with ongoing HIV exposure risk, transition immediately from nPEP to PrEP after completing the 28-day course, with HIV testing at completion before starting PrEP 1. This seamless transition prevents gaps in protection.